Evidence map›Paper›PMID 40400016›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2025

Factors contributing to non-compliance with on-demand treatment guidelines in hereditary angioedema.

Stephen D Betschel, Jonny Peter, William Lumry, Hilary Longhurst, Constance H Katelaris, Sally van Kooten, Markus Heckmann, Neil Malloy, Julie Ulloa, Sherry Danese and 1 more

Abstract read
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stephen D BetschelDepartment Division Director Clinical Immunology and Allergy, Staff Clinical Immunologist and Allergist, University of Toronto, St. Michael's Hospital, 36 Toronto St, Suite 700, Toronto, ON, M5C 2C5, Canada. Stephen.Betschel@unityhealth.to.
Jonny PeterUniversity of Cape Town, Cape Town, South Africa.
William LumryAARA Research Center, Dallas, TX, USA.
Hilary LonghurstDepartment of Immunology, University of Auckland, Auckland City Hospital, Te Toka Tumai, Auckland, New Zealand.
Constance H KatelarisCampbelltown Hospital and Western Sydney University, Sydney, NSW, Australia.
Sally van KootenKalVista Pharmaceuticals, Inc, Cambridge, MA, USA.
Markus HeckmannKalVista Pharmaceuticals, Inc, Cambridge, MA, USA.
Neil MalloySummit Global Health, Old Lyme, CT, USA.
Julie UlloaOutcomes Insights, Agoura Hills, CA, USA.
Sherry DaneseOutcomes Insights, Agoura Hills, CA, USA.
Markus MagerlInstitute of Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHereditary angioedema (HAE) is a rare genetic disorder characterized by painful and potentially life-threatening tissue swelling due to a deficiency or dysfunction of the C1 esterase inhibitor protein. Despite the availability of comprehensive on-demand treatment guidelines, compliance to guideline recommendations remains suboptimal, resulting in persisting unmet need.

methodsThis observational, online survey was conducted between September 6, 2022, and October 19, 2022 to understand the behaviors and perspectives of individuals in the US with hereditary angioedema (HAE). Participants were recruited by the US Hereditary Angioedema Association and were eligible if they were US residents with clinician-diagnosed HAE type I or II and had experienced at least one HAE attack. The survey included multiple-choice, rank-order, and scale-based responses using a 5-point Likert scale for agreement and an 11-point Likert scale for anxiety. Statistical analysis was performed using Microsoft Excel, summarizing continuous variables as means, medians, and ranges, and categorical variables as frequency distributions and percentages.

resultsA total of 107 out of 155 participants completed the survey (mean age = 41 years; 80.4% female). Half of the respondents used both prophylaxis and on-demand therapy, while the other half used on-demand therapy only. Icatibant was the most commonly used on-demand treatment (78.5%). The survey revealed that 57% of respondents did not treat all HAE attacks, and only 14% treated attacks immediately. Delays in treatment were common, with a mean time to treatment of 2.4 h, and younger patients were less likely to carry on-demand treatment. Reasons for delaying treatment included the perceived severity of the attack, lack of on-demand treatment availability, and pain associated with treatment. Additionally, 32.7% of respondents experienced the return of an HAE attack after initial treatment, with those delaying treatment more likely to experience recurrence. The survey also found that delayed treatment led to more severe attacks and longer recovery times, impacting work, social activities, and overall quality of life.

conclusionsAlthough guidelines recommend early treatment of HAE attacks, many respondents do not treat immediately. This finding underscores the importance of incorporating open patient-physician communication to improve guideline compliance and the management of HAE.

Indexed as

ComplianceGuideline recommendationsHereditary angioedemaOn-demand treatmentSurvey

Identifiers

PMID40400016
PMCPMC12093744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.